BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24366195)

  • 1. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
    Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
    Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.
    Yang H; Li H; Wang Z; Gao J; Guo Y
    Urol Int; 2013; 91(4):456-61. PubMed ID: 23948854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer.
    Yun SJ; Jeong P; Kim WT; Kim TH; Lee YS; Song PH; Choi YH; Kim IY; Moon SK; Kim WJ
    Int J Oncol; 2012 Nov; 41(5):1871-8. PubMed ID: 22961325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
    Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
    J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.
    García-Baquero R; Puerta P; Beltran M; Alvarez M; Sacristan R; Alvarez-Ossorio JL; Sánchez-Carbayo M
    J Urol; 2013 Aug; 190(2):723-30. PubMed ID: 23485510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
    Offersen BV; Knap MM; Horsman MR; Verheijen J; Hanemaaijer R; Overgaard J
    Acta Oncol; 2010 Nov; 49(8):1283-7. PubMed ID: 20843171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
    Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
    Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
    Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
    J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.